Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease

Aging is by far the most prominent risk factor for Alzheimer's disease (AD), and both aging and AD are associated with apparent metabolic alterations. As developing effective therapeutic interventions to treat AD is clearly in urgent need, the impact of modulating whole-body and intracellular m...

Descripción completa

Detalles Bibliográficos
Autores principales: Austad, Steven N., Ballinger, Scott, Buford, Thomas W., Carter, Christy S., Smith, Daniel L., Darley-Usmar, Victor, Zhang, Jianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897048/
https://www.ncbi.nlm.nih.gov/pubmed/35256932
http://dx.doi.org/10.1016/j.apsb.2021.06.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897048/
https://www.ncbi.nlm.nih.gov/pubmed/35256932
http://dx.doi.org/10.1016/j.apsb.2021.06.014

Ejemplares similares